AVDL Avadel Pharmaceuticals PLC ADRs

Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the United States, France, and Ireland. Its commercial products that are used in the hospital setting include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection that is used for the treatment of hypotension occurring in the setting of anesthesia; and Akovaz, an ephedrine sulfate injection for treating hypotension, as well as Noctiva for treating nocturia due to nocturnal polyuria. The company owns and develops drug delivery platforms, such as Micropump, a microparticulate system that allows the development of modified and/or controlled release of solid and oral dosage formulations of drugs; LiquiTime, which allows development of modified/controlled release liquid suspension formulations; Trigger Lock that allows development of abuse-resistant modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, a hydrogel depot technology that allows the development of extended/modified release of injectable dosage formulations of drugs. Its product candidates also comprise REST-ON, which is in Phase III clinical trial for the treatment of daytime sleepiness and cataplexy in patients suffering from narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. The company was founded in 1990 and is headquartered in Dublin, Ireland. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.

$8.21  +0.07 (0.86%)
As of 12/06/2021 15:59:58 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Small cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—Specialty &
Index country:  Ireland
Country of incorporation:  Ireland
IPO date:  01/03/2017
Outstanding shares:  58,620,088
Average volume:  535,149
Market cap:   $499,443,150
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    05337M104
ISIN:        US05337M1045
Sedol:      BDTZ028
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   4.82
PS ratio:   0.00
Return on equity:   -67.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy